Full retail prices remain high, and some programs exclude certain groups
1-5 Despite the substantial burden of PADparticularly among womensex-based differences in its epidemiology, clinical presentation, functional impact, treatment strategies, and outcomes remain incompletely characterized and insufficiently appreciated in both research and clinical practice
As the adverse health outcomes associated with obesity become increasingly publicized, the provider perspective on the condition has shifted, and providers across all specialties feel progressively more interested in writing off-label prescriptions for diabetes GLP-1s to treat obesity 3
But if the question is which treatment patients can actually explore now with an experienced medical team, tirzepatide is the more usable answer today
We welcome recommendations and comments about our customer service, delivery, packaging or how much we care for you, naturally :-) Thank you for your feedback!